Michael Jay Ross - 15 Jun 2022 Form 4 Insider Report for Xilio Therapeutics, Inc. (XLO)

Reporting relationship: Director
Issuer ticker: XLO
Reported as of: 15 Jun 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 17 Jun 2022, 16:30:50 UTC
Prior SEC filing: 21 Oct 2021
Next SEC filing: 08 Oct 2026
Source filing: View source filing
Reporting owner signature: /s/ Chris Frankenfield, Attorney-in-Fact

Key filing fact

Michael Jay Ross filed Form 4 for Xilio Therapeutics, Inc. (XLO) on 17 Jun 2022.

Key facts

This page summarizes Michael Jay Ross's Form 4 filing for Xilio Therapeutics, Inc. (XLO).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 17 Jun 2022, 16:30.

Change

Previous filing in this sequence was filed on 21 Oct 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

XLO transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +13,200
Change %
Price: $0.000000
Shares after: 13,200
Date: 15 Jun 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 13,200
Exercise price: $2.28
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option award was granted on June 15, 2022 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 15, 2023 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service as a director of the Issuer through the vesting date.